参考文献/References:
[1] MUI U N, HALEY C T, TYRING S K. Viral oncology: molecular biology and pathogenesis[J]. Journal of Clinical Medicine, 2017, 6(12): 111.
[2] ABUSALAH M A H, GAN S H, AL-HATAMLEH M AI, et al. Recent advances in diagnostic approaches for epstein–Barr virus[J]. Pathogens, 2020, 9(3): 226.
[3] SMATTI M K, AL-SADEQ D W, ALI N H, et al. Epstein-barr virus epidemiology, serology, and genetic variability of LMP-1 oncogene among healthy population: an update[J]. Frontiers in Oncology, 2018, 8: 211.
[4] KIM S J, CHOI J Y, HYUN S H,et al. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis[J]. The Lancet: Haematology, 2015, 2(2):e66-e74.
[5] AU Wingyan, PANG Annie, CHOY C, et al. Quantification of circulating Epstein-barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients[J]. Blood, 2004, 104(1): 243-249.
[6] TISI M C, CUPELLI E, SANTANGELO R, et al. Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma[J]. Leukemia & Lymphoma, 2016, 57(3): 628-634.
[7] MONTGOMERY N D, RANDALL C, PAINSCHAB M, et al. High pretreatment plasma Epstein-barr virus (EBV) DNA level is a poor prognostic marker in HIV-associated, EBV-negative diffuse large B-cell lymphoma in Malawi[J]. Cancer Medicine, 2020, 9(2): 552-561.
[8] OKAMOTO A, YANADA M, INAGUMA Y, et al. The prognostic significance of EBV DNA load and EBER status in diagnostic specimens from diffuse large B-cell lymphoma patients[J]. Hematological Oncology, 2017, 35(1): 87-93.
[9] STEVENS S J, PRONK I, MIDDELDORP J M. Toward standardization of Epstein-barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen[J]. Journal of Clinical Microbiology, 2001, 39(4): 1211-1216.
[10] SOLASSOL J, KREUZER K A, LASS U, et al. Epstein-barr virus DNA quantitation assessed by a real-time polymerase chain reaction in a case of Burkitt’s lymphoma[J].Leuk Lymphoma,2001,41(5-6):669-673.
[11] KABYEMERA R,MASALU N,RAMBAU P, et al. Relationship between non-Hodgkin’s lymphoma and blood levels of Epstein-barr virus in children in north-western Tanzania:a case control study[J]. BMC Pediatrics, 2013, 13(1): 4.
[12] VELAVAN T P. Epstein-barr virus,malaria and endemic burkitt lymphoma[J]. EBio Medicine, 2019, 39(1): 13-14.
[13] CARBONE A, GLOGHINI A, DOTTI G. EBV-associated lymphoproliferative disorders: Classification and treatment[J]. Oncologist, 2008, 13(5): 577-585.
[14] OCHI N, YAMANE H, YAMAGISHI T, et al. Methotrexate-induced lymphoproliferative disease: Epstein-barr virus-associated lymphomatoid granulomatosis[J]. Journal of Clinical Oncology, 2013, 31(20): e348-e350.
[15] COSTINIUK C T, KARAMCHANDANI J, BESSISSOW A, et al. Angiocentric lymph proliferative disorder (lymphomatoid granulomatosis) in a person with newly-diagnosed HIV infection: a case report[J]. BMC Infectious Diseases, 2018, 18(1): 210.
[16] 张静, 岳磊, 李颖璐.NK/T细胞淋巴瘤患者外周血EB病毒检测价值分析[J].中国实验血液学杂志, 2017, 25(2): 460-464. ZHANG Jing, YUE Lei, LI Yinglu. Clinical significance of peripheral blood EB virus detection in NK/T cell lymphoma patients [J]. Journal of Experimental Hematology,2017,25(2): 460-464.
[17] KWONG Y L, PANG A W K, LEUNG A , et al. Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance[J]. Leukemia, 2014, 28(4): 865-870.
[18] FEI Qian,TIAN Xiaokang,WU Jing,et al. Prognostic significance of Epstein-barr virus DNA in NK/T-cell lymphoma: a meta-analysis[J]. Onco Targets and Therapy,2018,11:997-1004.
[19] SUZUKI R, YAMAGUCHI M, IZUTSU K, et al. Prospective measurement of Epstein-barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type[J]. Blood, 2011, 118(23): 6018-6022.
[20] CHO J, KIM S J, PARK S, et al. Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma[J]. Annals of Hematology, 2018, 97(8): 1427-1436.
[21] KIM S J, YOON D H, JACCARD A, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis[J]. Lancet Oncology, 2016, 17(3): 389-400.
[22] KIMURA H, KWONG Y L. EBV viral loads in diagnosis, monitoring, and response assessment[J]. Frontiers in Oncology, 2019, 9: 62.
[23] ZHOU Yuanping, ATTYGALLE A D, CHUANG S S, et al. Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load[J]. British Journal of Haematology, 2007, 138(1): 44-53.
[24] DELFAU-LARUE M H, DE LEVAL L, JOLY B, et al. Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA[J]. Haematologica, 2012, 97(10): 1594-1602.
[25] LIANG Jinhua, LU Luo, ZHU Huayuan, et al. The prognostic role of circulating Epstein-barr virus DNA copy number in angioimmunoblastic T-cell lymphoma treated with dose-adjusted EPOCH[J]. Cancer Research and Treatment, 2019, 51(1): 150-157.
[26] GANDHI M K, TELLAM J T, KHANNA R. Epstein-barr virus-associated Hodgkin’s lymphoma[J]. British Journal of Haematology, 2004, 125(3): 267-281.
[27] PARK J H, YOON D H, KIM S, et al. Pretreatment whole blood Epstein-barr virus-DNA is a significant prognostic marker in patients with Hodgkin lymphoma[J]. Annals of Hematology, 2016, 95(5): 801-808.
[28] SINHA M, RAO C R , SHAFIULLA M, et al. Plasma Eepstein-barr viral load in adult-onset hodgkin lymphoma in South India[J]. Hematology/Oncology and Stem Cell Therapy, 2016, 9(1): 8-13.
[29] DINAND V, SACHDEVA A, DATTA S, et al. Plasma Epstein barr virus (EBV) DNA as a biomarker for EBV associated hodgkin lymphoma[J]. Indian Pediatrics, 2015, 52(8): 681-685.
[30] JUN-ICHI K, YASUKO K, AKIHISA S, et al. Viral DNA loads in various blood components of patients with Epstein-barr virus–positive T/NK cell lymphoproliferative diseases[J]. J Infect Dis，2019, 220(8):1307-1311.
[31] 陈天明, 邓志娟, 胡冰, 等.EB病毒阳性淋巴组织增殖性疾病13例临床与病理特征[J]. 中华儿科杂志, 2018, 56(10):759-764. CHEN Tianming, DENG Zhijuan, HU Bing,et al. Clinical and pathological features of 13 children with Epstein-barr virus-positive lymphoproliferative disease [J]. Chinese Journal of Pediatrics,2018,56(10): 759-764.
[32] KAWAMOTO K, MIYOSHI H, SUZUKI T, et al. A distinct subtype of Epstein-barr virus-positive T/NK-cell lymphoproliferative disorder: adult patients with chronic active Epstein-Barr virus infection-like features[J]. Haematologica, 2018, 103(6): 1018-1028.
[33] ARAI A. Advances in the study of chronic active Epstein-barr virus infection: clinical features under the 2016 WHO classification and mechanisms of development[J]. Frontiers in Pediatrics, 2019, 7: 14.
[34] ARAI A, YAMAGUCHI T, KOMATSU H, et al. Infectious mononucleosis accompanied by clonal proliferation of EBV-infected cells and infection of CD8-positive cells[J]. International Journal of Hematology, 2014, 99(5): 671-675.
[35] IKUTA K, SAIGA K, DEGUCHI M, et al. Epstein-barr virus DNA is detected in peripheral blood mononuclear cells of EBV-seronegative infants with infectious mononucleosis-like symptoms[J]. Virus Genes, 2003, 26(2): 165-173.
[36] CAO Pengfei,ZHANG Meili,WANG Wei, et al. Fluorescence in situ hybridization is superior for monitoring Epstein-barr viral load in infectious mononucleosis patients[J]. BMC Infectious Diseases, 2017, 17(1): 323.
[37] 喻晶, 王琳, 卢丽华, 等.淋巴细胞及血浆EB病毒DNA在EBV感染相关疾病中表达的研究[J].现代检验医学杂志, 2017, 32(6):15-18. YU Jing, WANG Lin, LU Lihua ,et al. Expression of Epstein-barr virus DNA in peripheral blood lymphocytes and plasma in patients with EBV-associated diseases [J]. Journal of Modern Laboratory Medicine, 2017,32(6):15-18.
[38] IKEDA T, GION Y, YOSHINO T, et al. A review of EBV-positive mucocutaneous ulcers focusing on clinical and pathological aspects[J]. Journal of Clinical and Experimental Hematopathology, 2019, 59(2): 64-71.
[39] DOJCINOV S D, VENKATARAMAN G, RAFFELD M, et al. EBV positive mucocutaneous ulcer-a study of 26 cases associated with various sources of immunosuppression[J]. The American Journal of Surgical Pathology, 2010, 34(3): 405-417.
[40] HART M, THAKRAL B, YOHE S, et al. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder[J]. The American Journal of Surgical Pathology, 2014, 38(11): 1522-1529.